1h Free Analyst Time
The publisher's latest disease pipeline guide Chemotherapy Induced Anemia - Drugs In Development, 2022, provides an overview of the Chemotherapy Induced Anemia (Toxicology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Chemotherapy-induced anemia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness, cognitive impairment, loss of sexual desire, inability to perform daily functions and/or depression associated with anemia. The predisposing factors include age, co-morbidities, time course of therapy.
Report Highlights
The publisher's latest pipeline guide Chemotherapy Induced Anemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chemotherapy Induced Anemia (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 2, 1, 5 and 2 respectively.
Chemotherapy Induced Anemia (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Anemia (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Anemia (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chemotherapy Induced Anemia (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chemotherapy Induced Anemia (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Anemia (Toxicology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Anemia (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of TablesList of Figures
Introduction
Report Coverage
Chemotherapy Induced Anemia - Overview
Chemotherapy Induced Anemia - Therapeutics Development
Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chemotherapy Induced Anemia - Companies Involved in Therapeutics Development
Avesthagen Ltd
FibroGen Inc
General Biologics Inc
Imagine Pharma LLC
Jecho Biopharmaceuticals Co Ltd
Panacea Biotec Ltd
PharmaEssentia Corp
PhytoHealth Corp
Resilience Biotechnologies Inc
SBI Pharmaceuticals Co Ltd
Sumitomo Dainippon Pharma Oncology, Inc
UBI Pharma Inc
Vifor Pharma Ltd
Zydus Lifesciences Ltd
Chemotherapy Induced Anemia - Drug Profiles
(aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile
Product Description
Mechanism Of Action
History of Events
darbepoetin alfa - Drug Profile
Product Description
Mechanism Of Action
darbepoetin alfa - Drug Profile
Product Description
Mechanism Of Action
desidustat - Drug Profile
Product Description
Mechanism Of Action
History of Events
epoetin alfa - Drug Profile
Product Description
Mechanism Of Action
erythropoietin - Drug Profile
Product Description
Mechanism Of Action
ferric carboxymaltose - Drug Profile
Product Description
Mechanism Of Action
History of Events
Fusion Protein to Agonize EPOR for Chemotherapy Induced Anemia and Renal Anemia - Drug Profile
Product Description
Mechanism Of Action
History of Events
itacnosertib - Drug Profile
Product Description
Mechanism Of Action
History of Events
JL-14001 - Drug Profile
Product Description
Mechanism Of Action
P-1116 - Drug Profile
Product Description
Mechanism Of Action
PHEP-01 - Drug Profile
Product Description
Mechanism Of Action
roxadustat - Drug Profile
Product Description
Mechanism Of Action
History of Events
TBI-304H - Drug Profile
Product Description
Mechanism Of Action
History of Events
Chemotherapy Induced Anemia - Dormant Projects
Chemotherapy Induced Anemia - Discontinued Products
Chemotherapy Induced Anemia - Product Development Milestones
Featured News
Aug 25, 2021: FibroGen announces positive topline results from phase 2 clinical trial of roxadustat for the treatment of chemotherapy induced anemia
Jul 23, 2020: Zydus receives approval from USFDA to initiate clinical trials of Desidustat in cancer patients receiving chemotherapy
Sep 26, 2019: FibroGen announces initiation of phase 2 clinical trial of Roxadustat for the treatment of anemia in cancer patients receiving chemotherapy
Feb 27, 2019: Tolero Pharmaceuticals to present new data evaluating investigational agent TP-0184 at AACR Annual Meeting 2019
Mar 11, 2015: Therapure Innovations Receives FDA Approval to Proceed with a Phase 1 Clinical Trial of Its Novel Anemia Therapeutic TBI 304H
Oct 30, 2012: SBI Pharmaceuticals Submits a Phase-1 Clinical Trial CTA to MHRA for a Drug to Treat Cancer Chemotherapy-induced Anemia
Apr 24, 2012: SBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health
Oct 28, 2011: ALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology
Oct 21, 2011: ALA Study Results Presented at 39th Annual Meeting of Japanese Association for Acute Medicine
Oct 05, 2011: ALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting
Oct 03, 2011: ALA Study Results Presented at Japanese Society of Parasitology, 71st Meeting
Mar 18, 2011: Announcement of publication of ALA research in International Immunopharmacology
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
- Number of - Products under Development for Chemotherapy Induced Anemia, 2022
- Number of - Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
Chemotherapy Induced Anemia - Pipeline by FibroGen Inc, 2022
Chemotherapy Induced Anemia - Pipeline by General Biologics Inc, 2022
Chemotherapy Induced Anemia - Pipeline by Imagine Pharma LLC, 2022
Chemotherapy Induced Anemia - Pipeline by Jecho Biopharmaceuticals Co Ltd, 2022
Chemotherapy Induced Anemia - Pipeline by Panacea Biotec Ltd, 2022
Chemotherapy Induced Anemia - Pipeline by PharmaEssentia Corp, 2022
Chemotherapy Induced Anemia - Pipeline by PhytoHealth Corp, 2022
Chemotherapy Induced Anemia - Pipeline by Resilience Biotechnologies Inc, 2022
Chemotherapy Induced Anemia - Pipeline by SBI Pharmaceuticals Co Ltd, 2022
Chemotherapy Induced Anemia - Pipeline by Sumitomo Dainippon Pharma Oncology, Inc, 2022
Chemotherapy Induced Anemia - Pipeline by UBI Pharma Inc, 2022
Chemotherapy Induced Anemia - Pipeline by Vifor Pharma Ltd, 2022
Chemotherapy Induced Anemia - Pipeline by Zydus Lifesciences Ltd, 2022
Chemotherapy Induced Anemia - Dormant Projects, 2022
Chemotherapy Induced Anemia - Discontinued Products, 2022
List of Figures
- Number of - Products under Development for Chemotherapy Induced Anemia, 2022
- Number of - Products under Development by Companies, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Avesthagen Ltd
- FibroGen Inc
- General Biologics Inc
- Imagine Pharma LLC
- Jecho Biopharmaceuticals Co Ltd
- Panacea Biotec Ltd
- PharmaEssentia Corp
- PhytoHealth Corp
- Resilience Biotechnologies Inc
- SBI Pharmaceuticals Co Ltd
- Sumitomo
